ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Interactive diabetes case 9: Management of type 1 diabetes in a patient on glucocorticoid therapy – B3

Interactive diabetes case 9: Management of type 1 diabetes in a patient on glucocorticoid therapy – B3
Literature review current through: Jan 2024.
This topic last updated: Jun 26, 2023.

ANSWER — Incorrect.

First of all, this is not an optimal time to change the types of insulin used by the patient. A conversion to a glargine and lispro regimen usually requires some adjustment of doses, even in a well-controlled diabetic patient. In the present case, this variable would then be added to the hyperglycemic effect produced by the use of prednisone. The patient was well controlled before the start of prednisone, so little is to be gained from conversion to glargine and lispro.

  • Secondly, an intermediate-acting basal insulin (in particular, NPH insulin) given in the morning is probably the preferred basal insulin for a patient treated with a short-acting glucocorticoid such as prednisone once daily in the morning. The time course of action of NPH insulin roughly approximates the time course of the hyperglycemic effect of a short-acting glucocorticoid such as prednisone.

Return to the previous choice to try again. (See "Interactive diabetes case 9: Management of type 1 diabetes in a patient on glucocorticoid therapy – A2".)

Topic 4164 Version 7.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟